Exicure Inc (XCUR) - Total Liabilities
Based on the latest financial reports, Exicure Inc (XCUR) has total liabilities worth $10.66 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Exicure Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Exicure Inc's total liabilities have evolved over time, based on quarterly financial data. See Exicure Inc (XCUR) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Exicure Inc Competitors by Total Liabilities
The table below lists competitors of Exicure Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Iris Metals Ltd
AU:IR1
|
Australia | AU$478.76K |
|
Sambhaav Media Limited
NSE:SAMBHAAV
|
India | Rs111.34 Million |
|
Skillful Craftsman Education Tech
NASDAQ:EDTK
|
USA | $2.10 Million |
|
Kps AG
XETRA:KSC
|
Germany | €73.86 Million |
|
Capital Engineering Network Public Company Limited
BK:CEN
|
Thailand | ฿447.12 Million |
|
KSG Agro SA
WAR:KSG
|
Poland | zł27.86 Million |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
Greece | €18.91 Million |
|
Atomos Ltd
AU:AMS
|
Australia | AU$23.98 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Exicure Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see XCUR stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Exicure Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Exicure Inc (2015–2025)
The table below shows the annual total liabilities of Exicure Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.12 Million | +22.10% |
| 2024-12-31 | $8.28 Million | -3.10% |
| 2023-12-31 | $8.55 Million | +1.70% |
| 2022-12-31 | $8.41 Million | -84.33% |
| 2021-12-31 | $53.64 Million | +37.75% |
| 2020-12-31 | $38.94 Million | +12.81% |
| 2019-12-31 | $34.52 Million | +342.29% |
| 2018-12-31 | $7.80 Million | -13.40% |
| 2017-12-31 | $9.01 Million | -50.29% |
| 2016-12-31 | $18.13 Million | +1203.24% |
| 2015-12-31 | $1.39 Million | -- |
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more